The transgenic COX-2 overexpression operates the formation of mammary tumors and, in reverse elimination of COX-2, reduces tumor formation in rodent models, especially for breast, skin, and intestinal cancers [63]. This evidence concerns the gene PTGS2 and breast cancer.